Navigation Links
Ambit Announces Presentations At The 55th Annual Meeting Of The American Society Of Hematology (ASH)
Date:12/9/2013

SAN DIEGO, Dec. 9, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced four oral presentations given at the 55th Annual ASH Conference in New Orleans, with data highlighting the Company's lead drug candidate, quizartinib. 

Results of the Phase 2b Randomized, Open-Label, Study of Lower Doses of Quizartinib in Subjects with FLT3-ITD Positive Relapsed Acute Myeloid Leukemia (AML): The purpose of this study is to assess the efficacy and safety of lower doses of quizartinib in the treatment of patients 18-years or older with relapsed/refractory FLT3 ITD positive AML to further improve the benefit:risk assessment of quizartinib.

This preliminary analysis is based on data available through May 28, 2013 with a minimum of eight weeks of follow up since the last subject first visit.  A total of 76 patients were enrolled from May 21, 2012 to March 27, 2013.  Median age for all patients was 55 (19-77) and 92% were FLT3-ITD(+).  35 patients remained in follow-up at the time of the analysis, and are currently censored for overall survival.  The following key information was presented:

For dose of 30mg:

  • The CRc rate was 47 percent (5 percent CR+CRp, 42 percent CRi)
  • The rate of HSCT after quizartinib use was 32 percent
  • The median overall survival was 20.7 weeks, with 16/38 patients censored as they remained in follow-up at the time of the analysis
  • Of the 12 patients who were bridged to HSCT, the median overall survival was 31 weeks
  • Grade 2 or greater QT prolongation was 11%, with a 5% grade 3 rate and no grade 4 events
  • For dose of 60mg:

  • The
    '/>"/>

  • SOURCE Ambit Biosciences
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Ambit Announces Participation At Oppenheimer 24th Annual Healthcare Conference
    2. Ambit Biosciences Provides Regulatory Update Following FDA Meeting Regarding Quizartinib (AC220)
    3. Ambit Biosciences to Announce Third Quarter 2013 Financial and Operating Results and Conference Call
    4. Ambit Biosciences Corporation Announces Second Quarter 2013 Operational Results
    5. Ambit Biosciences to Announce Second Quarter 2013 Operational Results and Conference Call
    6. Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology
    7. Lo studio pubblicato su European Radiology esalta ulteriormente lutilizzo della tomosintesi al seno di Hologic nellambito dello screening del cancro con utilizzo della doppia lettura
    8. Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
    9. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
    10. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
    11. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/29/2015)... -- Eli Lilly and Company (NYSE: LLY ) ... Conference on Tuesday, June 9, 2015. Jeffrey Simmons ... will participate in a fireside chat at 2:20 p.m., ... webcast will be available on the "Webcasts & Presentations" ... A replay of the fireside chat will be available ...
    (Date:5/29/2015)... BOSTON , May 29, 2015 /PRNewswire/ ... custom automation, and contract manufacturing, and Vaxxas , ... drug delivery technology, have been named winners of the ... Nanopatch Jet Coating Instrument , an advanced technology platform ... development.  The award was announced last evening at the ...
    (Date:5/29/2015)... May 29, 2015  Epic Sciences announced today that ... from metastatic castrate resistant prostate cancer patients, at ... for Clinical Oncology. This application expands the investigational ... behind™ platform to characterize circulating tumor cell ... stage patients have heterogeneous clonal CTC populations harboring ...
    Breaking Medicine Technology:Lilly to Participate in Goldman Sachs Global Healthcare Conference 2Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 2Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 3Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 2Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 3
    ... Pa., Feb. 24 Kensey Nash Corporation (Nasdaq: ... an Investigational Device Exemption (IDE) application to the U.S. ... of the Company,s unique biomaterials technology for treating articular ... utilize the Company,s Cartilage Repair Device, which consists of ...
    ... LONDON, Feb. 23 MAP Pharmaceuticals, Inc. announced today ... Dose Budesonide (UDB) for the potential treatment of children ... control as assessed by changes from baseline in nighttime ... doses evaluated when compared with placebo. AstraZeneca (NYSE: ...
    Cached Medicine Technology:Kensey Nash Announces IDE Submission for Cartilage Repair Device 2Kensey Nash Announces IDE Submission for Cartilage Repair Device 3Kensey Nash Announces IDE Submission for Cartilage Repair Device 4AstraZeneca's Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints 2
    (Date:5/30/2015)... 30, 2015 "Despite having the most ... get better health outcomes than people in other developed ... always safe" states author Dr. John Patrick in his ... Unraveling and Solving the Complexities of Healthcare, John ... to the healthcare policy debate will understand. He arrives ...
    (Date:5/30/2015)... (PRWEB) May 30, 2015 Thousands of ... 2015’s Aesthetic Meeting, sponsored by the American Society for ... vendors on hand was Zeltiq, the parent company of ... space, CoolSculpting. With blazing growth, the one-of-a-kind device ... , Zeltiq is currently in the news for ...
    (Date:5/30/2015)... (PRWEB) May 30, 2015 Boston ... million in punitive and compensatory damages to a ... suffered serious complications following implantation of the company’s ... verdict rendered on May 28th in Delaware Superior ... compensatory damages after the jury found that the ...
    (Date:5/30/2015)... At 73 years old, Lynn Kendall ... which she attributes to a lifetime of being health-conscious. She ... the release of her new book titled “ Cook for ... for Health and Longevity” features a collection of recipes and ... food . It is designed to encourage a lifestyle of ...
    (Date:5/30/2015)... 30, 2015 Key Housing, a top-rated ... to announce their June 2015 featured apartment community: 388 ... San Francisco, Key Housing is helping those people looking ... is one of the tightest apartment markets in the ... and understandably anyone who requires temporary San Francisco corporate ...
    Breaking Medicine News(10 mins):Health News:"Health Attitude", a new book by Dr. John R. Patrick, explains the American healthcare system, what is wrong with it, and how to fix it. 2Health News:"Health Attitude", a new book by Dr. John R. Patrick, explains the American healthcare system, what is wrong with it, and how to fix it. 3Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 2Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 4Health News:Lynn Kendall Shows How to ‘Cook for Health and Longevity’ 2Health News:Lynn Kendall Shows How to ‘Cook for Health and Longevity’ 3Health News:San Francisco Corporate Housing Leader Key Housing Designates 388 Beale Street as Featured Community for June 2Health News:San Francisco Corporate Housing Leader Key Housing Designates 388 Beale Street as Featured Community for June 3
    ... of plastic surgery performed for cosmetic reasons // in ... performed. ,Researchers examined data from seven mammography registries ... of women with breast implants to those of women ... show breast implants decreased the sensitivity of mammography exams. ...
    ... number of new cancer cases and deaths from cancer ... survival rate of non-small-cell lung cancer patients after its ... anti-neoplastic medication that interferes with the growth of cancer ... body. ,As part of the International Adjuvant ...
    ... scan done six weeks after completing a combined treatment ... and distant metastases or secondary tumors in patients with ... has a direct influence on health management decisions. ... and neck cancer had a PET scan before and ...
    ... one that causes excessive absence from work. Many doctors recommend ... them to normal activity levels. But many people with lower ... ,A new study suggests people with low back pain can ... conducted among the employees of an airline company in the ...
    ... strongest risk factors for melanoma skin cancer.// Previous research also ... is detected early. ,New research shows patients who use ... to keep better track of new or changed moles. Researchers ... more atypical nevi, or pigmented moles that may change shape ...
    ... required for success in school are similar to those ... that one’s cognitive abilities predict success in the academic ... believe what is needed for job success is different ... the University of Illinois tested whether abilities related to ...
    Cached Medicine News:
    The ACMI™ line of laparoscopic hand instruments is designed to provide a wide selection of popular surgical devices to meet procedural needs....
    The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
    This probe coagulates bleeders while suction channel with trumpet valve simultaneously evacuates smoke....
    Inditherm's patient warming systems are being routinely used in clinical practice for the full range of surgical procedures and specialties. They use the very latest technology to give best available...
    Medicine Products: